Strategic partnerships Andelyn has a track record of collaborations with notable biotech players and foundations, including Evolyra Therapeutics, Drake Rayden Foundation, Jaguar Gene Therapy, and Solid Biosciences. This indicates openness to co-development and manufacturing partnerships that could be expanded with additional gene therapy targets and delivery modalities.

Scale and capacity With a 180,000-square-foot facility capable of clinical through commercial manufacturing and a demonstrated history of supporting over 450 cGMP clinical batches, Andelyn offers scalable production capabilities that can accommodate rising demand for viral vectors and gene therapies across multiple programs.

LVV platform Recent launches of the LVV Curator Platform and a dedicated lentiviral vector manufacturing platform signal a strong emphasis on standardized, streamlined LVV processes. This presents an opportunity to offer therapeutic candidates requiring LVV manufacturing support or to co-develop novel LVV-based therapies.

Therapy focus Active engagement in gene therapy for rare diseases such as limb-girdle muscular dystrophy and Phelan-McDermid syndrome positions Andelyn as a partner for programs targeting monogenic disorders, especially where viral vectors and AAV/LVV production are bottlenecks.

Financial and market readiness A revenue range of $100–250 million and a broad client base across clinical and commercial stages suggest the company has the financial stability and market credibility to negotiate longer-term CDMO engagements, capacity bookings, and multi-program collaborations with pharma and biotech partners.